PIK3CA and prostate cancer: Indeed, the inhibition of PI3K/AKT/mTOR activity by specific inhibitors leads to a decrease in the CSC population in nasopharyngeal carcinoma [133], glioma [74] pancreatic carcinoma [134], lung cancer [129,135], prostate cancer [126,131] and breast cancer [127].